Sinobiomed said its 82% owned subsidiary, Shanghai Wanxing Biopharmaceuticals, received a patent from the State Intellectual Property Office of the PRC. The patent protects a manufacturing technology used to create a compound that stimulates the re-growth of liver cells. Shanghai Wanxing has already completed preclinical work on the compound. The company expects to ask the SFDA for permission to begin Phase I clinical tests of the drug soon and to start those tests early next year. More details...

Stock Symbols: (OTCBB: SOBM)